会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 100. 发明授权
    • Therapeutic compounds containing xanthinyl
    • 含有黄原素的治疗化合物
    • US6100271A
    • 2000-08-08
    • US483871
    • 1995-06-07
    • J. Peter KleinAlistair J. LeighGail E. UnderinerAnil M. Kumar
    • J. Peter KleinAlistair J. LeighGail E. UnderinerAnil M. Kumar
    • C07D239/54A61K31/42A61K31/421A61K31/496A61K31/505A61K31/52A61K31/522A61P9/10A61P9/14A61P11/16A61P13/02A61P15/00A61P25/28A61P29/00A61P31/12A61P31/18A61P35/00A61P37/04A61P37/08A61P43/00C07C47/198C07C47/277C07C49/175C07C49/255C07C57/46C07C59/64C07C65/21C07C69/06C07C69/14C07C69/24C07C69/608C07C69/612C07C225/06C07C233/01C07D239/56C07D241/18C07D263/30C07D473/04C07D473/06C07D473/10C07D487/04C07D513/04C07D521/00
    • C07D487/04C07D473/04C07D473/06C07D473/10C07D513/04
    • Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:CORE MOIETY --(R).sub.jwherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyallyl; --A(R.sub.5).sub.m, A being N or O, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.
    • 具有至少一个羧酸,酯或酰胺取代的侧链的治疗化合物具有下式:CORE MOIETY - (R)j,其中j是1至3的整数。 核心部分是非环状或环状的(碳环或杂环)。 R可以选自氢,卤素,羟基,氨基,取代或未取代的C(1-10)烷基,C(2-10)烯基,碳环或杂环基,并且至少一个R具有式I:其中: 或两个p为整数,否则p为2; n为3〜20的整数。 R1选自取代和未取代的CH 2; NR 1,R 3为氢,取代或未取代的C 1-20烷基,C(1-20)烷氧基,C(2-20)烯基或C(1-20)羟基烷基或碳环或杂环基; O; -CHR4O-,R4是取代或未取代的C(1-20)烷基,C(1-20)烷氧基,C(2-20)烯基,C(1-20)羟基烷基或R2和R4连接形成取代的 或具有4-7个环原子的未取代的杂环,-CHR4O-的醚基-O-是杂环的成员。 R2选自氢; 卤素; 取代或未取代的C(1-10)烷基; C(1-10)烷氧基; C(2-10)烯基; C(1-10)羟基烯基; -A(R5)m,A是N或O,m是一个或两个,R5是氢,取代或未取代的C(1-10)烷基,C(1-10)烷氧基,C(2-10)烯基 或C(1-10)羟烷基)或碳环或杂环基。 R 1中的至少一个为NR 3,O或-CHR 4 O-,或R 2为-A(R 5)m。 这些化合物及其药物组合物可用作通过介导对外部刺激的信号反应的特异性细胞内信号通路的细胞内信号传导的疾病的治疗。